Introduced
by
To prohibit pharmacies or a pharmacists from entering a contract that forbids their telling customers the current selling price of other brand name or generic versions of a drug, or interchangeable biological drug products.
Referred to the Committee on Health Policy
Reported without amendment
Refer to the Committee on Ways and Means with the recommendation that the substitute (H-1) be adopted.
Referred to the Committee on Ways and Means
